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Abstract.  CD22/3 is a B cell-restricted phospho- 
protein expressed on the surface of mature resting 
B cells. It mediates interactions with other cells partly 
or exclusively via recognition of ot2-6-1inked  sialic 
acids on glycoconjugates. The sialylated N-linked 
oligosaccharides recognized best by CD22/~ are com- 
mon to many glycoproteins, suggesting that additional 
regulatory mechanisms may exist. Since the exocyclic 
side chain of sialic acid is required for recognition, we 
explored the effects of a naturally occurring modifica- 
tion of the side chain, 9-O-acetylation. Semisynthetic 
N-linked oligosaccharides terminating with 9-0- 
acetylated, o~2-6-1inked sialic acids showed markedly 
reduced binding to CD22/~ relative to their non-O- 
acetylated counterparts. Murine lymphoid cells were 
probed for natural CD22/~ ligands that might be 
O-acetylated using recombinant soluble forms of 
CD22/~ (CD22/3Rg)  and influenza C esterase (CHE-Fc, 
which specifically removes 9-O-acetyl esters from 
sialic acids). By flow cytometry analysis, CD22/3Rg 
binding to splenic B cells and a subset of T cells was 
increased by pretreatment with CHE-Fc, indicating that 
some potential CD22/3 ligands are naturally "masked" 
by 9-O-acetylation. Unmasking of these CD22/3 
ligands by removal of 9-O-acetyl esters from intact 
splenocytes substantially increases their CD22/3- 
dependent adhesion in an in vitro adhesion assay. 
Probing of murine lymphoid tissue sections by 
CD22/~Rg  and CHE-Fc treatment demonstrates region- 
ally restricted and differentially expressed patterns of 
distribution between masked and unmasked ligands. 
For example, lymph node-associated follicular B cells 
express high levels of CD22/~ ligands, none of which 
are masked by 9-O-acetylation. In contrast, the ligands 
on lymph node-associated dendritic cells are almost 
completely masked by 9-O-acetylation, suggesting that 
masking may regulate interactions between CD22/3- 
positive B cells and dendritic cells. In the thymus, 
only medullary cells express CD22/3 ligands, and a 
significant portion of these are masked by 9-0- 
acetylation, particularly at the cortical-medullary 
junction. Thus, 9-O-acetylation of sialic acids on im- 
mune cells is in a position to negatively regulate 
CD22B adhesion events in a manner depending on 
both cell type and tissue localization. 
I 
NTERCELLULAR  adhesion between leukocytes involves a 
variety of receptor/ligand pairs  that are required for 
eliciting  immune responses  (37).  One such adhesion 
molecule is a B cell-restricted glycoprotein of the immuno- 
globulin  superfamily,  CD22B (7,  8,  38,  39, 49).  First ex- 
pressed within the interior of pre-B cells, CD22B is mobi- 
lized  to  the  cell  surface  during  maturation,  coinciding 
temporally with the surface expression of IgD (7). Two hu- 
man CD22 cDNAs designated CD22c¢ and CD22/~ have been 
isolated,  and their predicted sequences share homology to 
several adhesion molecules, including the neural cell adhe- 
sion  molecule,  myelin-associated  glycoprotein,  and  car- 
cinoembryonic antigen (38, 49). The two differ only in that 
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CD22/~ contains seven extraceUular Ig domains,  whereas 
CD22o~ lacks  Ig domains 3 and 4  (38, 49).  While some 
differences in the binding properties of the two recombinant 
forms have been reported, CD22/~ appears to be the predom- 
inant cell surface form in both human and murine systems 
(41). Much evidence indicates the involvement of CD22~ in 
B cell proliferation.  A fraction of CD22/~ coexists with sur- 
face IgM on the surface of naive B ceils (7), In response to 
IgM cross-linking,  CD22-positive lymphocytes show selec- 
tive increases in calcium flux (26), specific cytoplasmic  tyro- 
sine residues on CD22~/are rapidly phosphorylated (32), 
and the cell surface expression  of CD22/3 is quickly en- 
hanced beyond basal  levels.  However,  over longer time 
periods, surface expression is strikingly reduced (7, 20, 32). 
Cross-linking of CD22/~ facilitates the calcium mobilization 
induced by cross linking surface IgM (25). 
On T cells, various isoforms of the common leukocyte an- 
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soluble form of CD22/5 precipitates CD45, as well as a num- 
ber of other lymphocyte glycoprotein ligands (34). Although 
adhesion molecules with extracellular Ig domains generally 
mediate  recognition  by  protein-protein  interactions,  the 
common feature of all CD22/3-mediated interactions  is an 
absolute requirement for sialic acids as a part of the ligand 
(2, 8, 27, 28, 34, 39). In this regard, we have demonstrated 
that CD2213 specifically interacts with free oligosaccharides 
(derived from either the natural ligands or prepared syntheti- 
cally) that terminate  with one or more a2-6-1inked  siaiic 
acids, and that other anomeric linkages do not confer inter- 
action (27, 28). Since the expression of the ot2-6 sialyltrans- 
ferase  (ot2-6  STN, I which  selectively attaches  sialic  acid 
in ~2-6 linkage to N-linked oligosaccharides) is relatively 
widespread, such o~2-6-sialylated-oligosaccharides are rela- 
tively common on glycoproteins. This raises the question of 
how CD22/3 selectively recognizes its specific counterrecep- 
tors.  One  possibility  is  that  ot2-6-1inked  sialic  acids  are 
sometimes modified in a manner that abolished interaction 
with CD22/3. The term %ialic acid" actually refers to a di- 
verse  family  of molecules  derived  from  the  nine-carbon 
acidic  sugar  N-acetyl-neuraminic  acid  (Neu5Ac,  Fig.  1, 
structure A).  Among the more common of these are mod- 
ifications of the exocyclic side chain by O-acetyl ester groups 
at  C7  and  C9,  generating  7-O-acetyl-N-acetyl neuraminic 
acid (Neu5, 7Ac2) and 9-O-acetyl-N-acetyl neuraminic acid 
(Neu5,  9Ac2), respectively (31,  44).  Since O-acetyl esters 
at the C7 position spontaneously migrate to the C9 position 
at physiologic extracellular pH (16, 44), Neu5, 9Ac2 (Fig.  1, 
structure D) predominates  on cell surface glycoconjugates 
(5). We have previously demonstrated that selective chemi- 
cal oxidation of C8 and C9 (Fig.  1, structures B and C) by 
mild periodate treatment (27, 34) abolishes CD22/~ recogni- 
tion.  Thus,  the  natural  side  chain  modification  of  9-0- 
acetylation is a candidate for negative regulation of CD22~ 
interactions. 
To pursue this possibility, we used both conventional tech- 
niques, as well as a novel reagent derived from the influenza 
C  virus  9-O-acetyl-sialic  acid-specific  esterase  (17).  We 
demonstrate  here  that 9-O-acetylation  can  indeed  "mask" 
recognition of synthetic and natural ligands by CD22/$, and 
that it can also abrogate  CD22~-dependent  cell  adhesion. 
Additionally,  immunohistological  studies of lymphoid  tis- 
sues show that potential ligands "masked" by 9-O-acetylation 
are present on specific cell types and in distinctive regional 
distributions. 
Materials and Methods 
Materials 
Most of the chemicals and some of the reagents  used were from Sigma 
Chemical Co. (St. Louis, MO). The following were obtained from the cora- 
l.  Abbreviations  used  in this paper:  c~2-6 STN,  c~2-6 sialyltransferase; 
CD2213Rg, chimeric protein made of the first three extracdlular domains 
of  CD22/3,  fused  to  the  Fc  portion  of human IgGl;  CD22/3Rg-PAS, 
CD22/~Rg attached to protein A-Sepharose;  CHE-Fc,  chimeric protein 
made of InfCHE (Influenza C hemagglutinin-esterase with the fusion pep- 
tide eliminated by mutation) and the F,¢ portion of human IgGl; CHE-FcD, 
diisopropyl fluorophosphate-treated CHE-Fc (esterase activity irreversibly 
inactivated);  CMP, cytidine monopbosphate; Neu5Ac, N-acetyl-neuraminic 
acid;  Neu5,gAc2, 9-O-acetyl-N-acetyl  neuraminic acid;  NeuSGc,  N-gly- 
colyl-neuraminic ac.d;  STN,  sialyltransferase  catalyzing attachment of 
Neu5Ac to N-linked oligosaccharides. 
mercial sources indicated: diisopropyl  fluorophosphate,  Aldrich Chemical 
Co.  (Milwaukee,  WI);  HPLC  solvents,  Fisher Scientific  (Tustin,  CA); 
asialo fetuin triantennary ollgosaccharide  (FT-02),  Dionex  Corporation; 
FITC-goat  anti-human IgGl,  Cappel  Laboratories  (Cochranville,  PA); 
phycoerythrin-conjugated  antimurine Thy  1.2  (pan  T  cell  marker)  and 
phycoerythrin conjugated antimurine B220 (pan B cell marker), PharMin- 
gen (San Diego,  CA).  c~2-6 STN was a generous gift from J. C. Paulson 
(Cytel,  La Jolla, CA). 
Synthesis of (CMP)-pH]NeuSAc Derivatives 
Cytidine monophosphate (CMP)-sialic acid synthase was purified from rat 
liver as described (29), and an enriched preparation from the 60% ammo- 
nium sulfate  cut was  used.  [9-3H-acetyl]Neu5,9Ac2  was  synthesized  by 
labeling  isolated  rat  liver  Golgi  vesicles  with  [3H-acetyl]acetylCoA, 
releasing sialic acids with Arthrobacter ureafasciens sialidase,  and purify- 
ing  them by  ion  exchange  chromatography as  described  (45).  [9-3H  - 
acetyl]Neu5,9Ac2  was purified away from unlabeled endogenous Neu5Ac 
by descending paper chromatography using ethanol/1 M ammonium acetate 
pH  6.5  (7:3)  as  a  solvent  system.  Regions  corresponding  to  [9-3H  - 
acetyl]Neu5,9Ac2 were eluted from paper in water and dried. To synthesize 
CMP-[9-3H-acetyl]Neu5,9Ac2,  2 i~Ci of [9-3H-acetyl]Neu5,9A¢2  was dried 
and resuspended in 100/~1  of 180 mM Tris, pH 7.0, 10 mM manganese chlo- 
ride, 3 mM eytidine triphosphate, and 5 mM dithiothreitol (12). After addi- 
tion of 100/zl of the CMP-sialic acid synthase preparation and incubation 
for 1 h at 37°C,  1 vol of ice-cold acetone was added to quench the reaction. 
Precipitates were removed by centrifugation at 13,000 g for 5 rain, the su- 
pernatant was dried, redissolved in ethanol, and spotted onto paper along- 
side standard [9-3H-acety/]Neu5,  9Ae2 and CMP-[14C]Neu5Ac. The paper 
chromatngram was developed  overnight  using the above solvent system, 
dried, cut into 1-cm strips (46 strips), and each was soaked in I rrd of water. 
Aliquots (1%) of each were counted and fractions corresponding to CMP- 
[9-3H-acetyl]Neu5,9Ac2  (which migrates between CMP-[14C]Neu5Ac and 
[9-3H-acetyl]Neu5,9Ac2)  were pooled and dried.  After purification, the 
final yidd of CMP-[9-3H-acetyl]Neu5,9Ac2  relative to starting [9-3H-ace - 
ty/]Neu5,9Ac2 was  typically  •15%.  Since the CMP-[9-3H-acetyl]Neu5, 
9Ae2 is relatively unstable,  it was used within 1 wk of synthesis. 
Synthesis of oL2-6-1inked NeuS,  gAcz on a 
Triantennary Oligosaccharide 
Asialotriantennary oligosaccharide  (1.5 ttg) was dried along with 300,000 
cpm of purified CMP-[9-3H-acetyl]Neu5,9Ac2,  and was resuspended in 20 
#1 of 100 mM sodium cacodylate pH 6.9 with 1 mg/ml BSA.  1-2 mU of 
c~2-6 STN was added and the reaction was allowed to proceed overnight at 
37°C.  This mixture was passed over an anion exchange column (Mono-Q; 
Pharrnacia)  to fractionate oligosaccharides  by charge (27), with the pH of 
the  elution buffer  lowered  to pH  7.0  to  retain 9-O-acetyl  esters.  The 
[3H-acety/]-labeled  siaiylated  oligosaccharides  elute from this column in 
order of increasing numbers of sialic  acid residues,  and residual [9-3H  - 
acetyl]NeuS,9Ac2  and  CMP-[9-3H-acetyl]NeuS,9Ac2  are  resolved  from 
these structures.  In this manner, the number of [9-3H-acetyl]NeuS,9Ac2 
groups incorporated into each oligosaccharide  peak is known. After desalt- 
ing each peak over a Bio-Gel P-4 column (BioRad Laboratories, Richmond, 
CA), these oligosaccharides  were either directly passed onto the CD22~Rg- 
PAS (chimeric protein made of the first  three extracellular domains of 
CD22/3,  fused to the Fc portion of human IgG1[CD22/3Rg] attached to 
protein A-Sepharose) column as described (27) or the remaining terminal 
B-galactose residues were sialylated to near completion by incubation with 
0.1-0.2 mM nonlabeled CMP-Neu5Ac and 1-2 mU of t~2-6 STN, giving tri- 
antermary  oligosaccharides  with two or three sialic acids in a2-6 linkage 
(assessed  by  Mono-Q  chromatography).  Thus,  the  number of  [9-3H  - 
acetyl]Neu5,9Ac2  and  Neu5Ac  groups  incorporated  into  each  labeled 
oligosaccharide  is known. In certain experiments,  complete siaiylation with 
nonlabeled CMP-Neu5Ac was carded out without previous charge fraction- 
ation, resulting in a heterogenous mixture of oligosaccharides  containing 
at least one and possibly two 9-O-acetyl groups.  Each of these oligosaccha- 
ride preparations was assessed for interaction with a CD22/3Rg-PAS column 
as described (27). The column elution profiles were compared to those of 
corresponding  non-O-acetylated  sialylated  derivatives  passed  over  the 
same CD22/3Rg-PAS column run on the same day. In experiments following 
[3H-acetyl] tracer exclusively incorporated into 9-O-acetyl  esters,  the re- 
suits might be confusing iftbe labile esters became detached from the oligo- 
saccharide.  However, aliquots of radioactivity during from the CD22/~Rg- 
PAS column continued to void on a Bio-Gel P-6 column, demonstrating  per- 
sistent attachment of the esters to the oligosaccharides  (data not shown). 
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Oiigosaccharides Terminated with rH]NeuSGc 
CMP-[3H]N-glycolyl-neuraminic  acid (Neu5Gc) was synthesized  and pu- 
rified as described above, except that the reaction  was performed at pH 8.0, 
and magnesium chloride was  substituted for manganese chloride (12). 
CMP-[3H]NeuSGe was used as a donor to transfer [3H]Neu5Gc to the non- 
reducing termini of asialo-biantennary N-linked oligosaccharides  using 
c~2-6 STN as described above. 
Isolation of  Murine Spleen Cells 
4-wk-old B6/SJLFj mice were killed by cervical dislocation, their spleens 
were scraped over a wire mesh into RPMI 1640 on ice, and the cell suspen- 
sion was passed through gauze  to remove debris. Cells were pelleted at 
1,500 rpm at 4°C for 5 min in an IEC centrifuge, resnspended in 4 vol of 
17 mM "lYis, pH 7.2, 140 mM ammonium chloride for 3 rain to lyse erythro- 
cytes, repelleted, and resuspended in RPMI 1640 on ice. Ceils isolated in 
this manner were 80-85% viable as judged by trypan blue dye exclusion. 
Production of CD22{3Rg, CHE-Fc, and CHE-FcD 
Recombinant  human CD22/~Rg (39) was kindly provided by I. Stamenkovic 
(Massachusetts General Hospital, Boston, MA). The soluble chimeric pro- 
tein  CHE-Fc,  consisting  of  the  extracellular  domain  of  Influenza  C 
hemagglutinin-esterase fused to the Fc portion  of human I8G1 was gener- 
ated and characterized as described elsewhere (17).  The modified  form 
CHE-FcD  was  generated by treating CHE-Fc  with  1 mM diisopropyl 
fluorophospbate  to inactivate  the esterase as described (17, 22). CHE-Fc 
specifically releases 9-O-acetyl esters from sialic acids (i.e., it is an ester- 
ase),  whereas CHE-FcD  specifically  recognizes and binds to 9-O-ace- 
tylated siaiic acids (for more details see reference 17 and Fig.  1). Because 
of the human Fc tails, binding of CD22/3Rg or CHE-FcD to murine tissues 
or cells can be detected with appropriate secondary reagents. 
Mild Periodate Treatment of  Isolated Cells 
Cells isolated as described were resuspended in either ice-cold PBS, pH 7.0, 
containing 3 mM sodium metaperiodate or PBS alone (control cells) for 20 
rain on ice. The cells were washed 3 × in PBS, pH 7.0, and were then treated 
with or without CHE-Fc (see below) to remove 9-O-ecetyl esters from cell 
surface sialic acids.  The cells were then stained for flow cytometry as de- 
scribed below. 
Removal of 9-O-Acetyl Esters from Cell Surface 
Sialic Acids 
About 5  x  106 cells were resuspended in 50 t~l Tris-buffered  saline,  pH 
7.0, containing 0.02% sodium azide (control cells) or 50 t~l Tris-buffered sa- 
line, pH 7.0, containing 0.02 % sodium azide with 20 ttg CHE-Fc.  ARer in- 
cubation at 37°C  on an end-over-end i'otator for 45 rain, the cells were 
washed 2×  in ice cold PBS, and were then stained for flow cytometry as 
described below. 
Flow Cytometry Analysis 
Cells (2  ×  106) having undergone sham treatment or treatment with mild 
periodate and/or CHE-Fe were washed in ice-cold PBS/0.02 % sodium azide 
and incubated on ice in 100 td of PBS/0.02 % sodium azide/1% BSA contain- 
ing  20  t~g/ml of CD22/3Rg  for 40  rain.  For  double-staining analysis, 
phycoerythrin-conjugated rat antimurine B220 (IgG2,) or rat-antimurine 
Thyl.2 flgG2a) were incubated along with CD22#Rg at concentrations of 
5 ~tg/mi. Cells were washed twice with ice-cold PBS/0.02%  sodium azide, 
and were resuspended in 100/~1 of PBS/0.02% sodium azide/l% BSA con- 
taining FITC-conjugated  goat anti-human IgG (1:50 dilution of 1 mg/ml). 
After incubation for 40 rain, cells were washed twice in PBS/0.02 % sodium 
azide and fixed in PBS/0.02 % sodium azide containing 2 % paraformaide- 
hyde. Isotype controls consisted of incubating cells with equivalent concen- 
trations of human IgG1 in place of CHE-Fe or CD22/~Rg. Stained fixed 
cells  were  analyzed on a  FACsca~  machine (Beckton Dickinson Im- 
munocytometry Systems,  Mountain View, CA). 
Cell Binding to CD22{3Rg 
Microtiter wells were coated overnight at 4°C with 0.1 mg/mi protein A in 
50 mM Tris-C1, pH 8.5, rinsed once with PBS, blocked for 3 h at 4°C with 
PBS,  1 mg/ral BSA, rinsed again, incubated with 50 ~l/well of CD22/~Rg 
(0.1 mg/ml) in PBS for 2 h, and finally rinsed three times with PBS. Murine 
splenoeytes,  aRer treatment with or without mild periodate (as above) 
and/or  CHE-Fe,  were  washed in PBS,  and were  added  (50 td  at  107 
ceils/ml) to quadruplicate sets of wells.  Cells were allowed to adhere for 
30 rain at 4"C, and nonadherent coils were removed by gently washing four 
times with ice-cold PBS.  The center of each well where cells were uni- 
formly attached was then photographed on an inverted microscope (×10 
phase objective), and the number of cells in the resulting photomicrograph 
were counted. As controls for nonspecific binding, cells were treated (sub- 
sequent to initial CHE-Fc treatment) with mild periodate as above and then 
added to wells containing CD22/3Rg. The binding of non-periodate-treated 
cells to wells lacking  CD22~Rg (protein A alone) was also examined. 
Immunohistological Analysis of Murine Lymphoid 
Tissues with CHE-FcD and CD22{3Rg 
Tissues were obtained from 4-wk-old B6/S/LF1 mice that were killed as de- 
scribed above, and were immediately suspended in OCT and frozen in liq- 
uid nitrogen. Freshly cut frozen sections from cervical lymph node, spleen, 
and thymus were fixed in ico-cold acetone (10 rain), endogenous peroxidase 
quenched with 0.03%  hydrogen peroxide in PBS (10 rain), and then in- 
cubated at 4"C (20 rain) with blocking solution (3% goat serum/l%BSA in 
HBSS). Sections were washed three times in HBSS and overlaid with 3 mM 
sodium metaperiodate in PBS or PBS alone (sham treatment) for 20 rain 
at 4°C and washed three times again in I-IBSS. Sections were then treated 
with CHE-Fc (20 ~g/ml) in blocking solution or blocking solution alone 
(controls)  at room temperature for 45 rain, washed three times again in 
HBSS and overlaid with CHE-FcD,  CHE-Fc,  or CD22/~Rg (20 ~tg/ml) in 
blocking solution at 4°C for 1 h, after which they were washed three times 
again in HBSS. Detection was achieved by sequential incubations with bi- 
otinylated goat anti-human IgG (1:100 dilution in blocking buffer)  and 
streptavidin-peroxidase  (1:100 of a 1 mg/ml solution in blocking buffer) for 
30 rain at room temperature with three HBSS washes after each incubation. 
Development was  achieved with 3-amino-9-ethylcarbazole-peroxide  and 
hematoxylin counterstain. In these analyses,  mild periodate treatment is 
used as a negative control for CD22/3Rg staining (see Fig.  1 for rationale), 
and CHE-Fe is used as a negative control for CHE-FeD staining. Mild peri- 
odate treatment does not nonspecificaily  inhibit the colorimetric develop- 
ment because high endothelial venule staining with L-seleetin receptor 
globulin done in parallel (data not shown) is actually enhanced by this treat- 
ment (23). Note that acetone fixation was used because formaldehyde fixa- 
tion results in decreased binding of CD22/~Rg (unpublished observations); 
consequently,  the preservation of cdlular detail is somewhat less than op- 
timal.  However,  the  resolution is  sufficient  to  permit the  conclusions 
reached. 
Results 
9-O-Acetylation of a2-6-1inked Sialic acid on N-linked 
Oiigosaccharides Abolishes Binding to CD22{3Rg 
Using a sensitive column assay with CD22~Rg bound to pro- 
tein  A-Sepharose,  we previously  demonstrated  that free 
N-linked  oligosaccharides  with ot2-6-1inked sialic  acids at 
their nonreducing termini bind to CD22~. The apparent bind- 
ing affinity  increases  with  increasing  numbers of  a2-6-1inked 
residues,  and it  is  abolished  by their  selective  oxidation  with 
mild  pcriodate  (see  Fig. I  for  chemistry  of  reaction)  (27,  28). 
To determine if  9-O-acetylation  of  a2-6-1inked sialic  acids 
on CD22/3 ligands  might also  influence  binding (see  Fig. I 
for  structure),  we used CMP-pH-acety/]Neu5,9Ac2 and a2-6 
STN to sialylate  an asialotriantennary  oligosaccharide,  cre- 
ating ot2-6-sialylated  structures  with varying numbers of 
[3H-acety/]Neu5,9Ac2  residues  (12,  48).  We chose to incor- 
porate radiolabel  into  the O-acetyl moiety rather  than the 
sialic  acid  core because these  esters  are  known to  be some- 
what labile  (44). Thus, only oligosaccharides  containing 
O-acetyl  groups  would be  detected  and analyzed.  After  sial- 
ylation,  the oligosaccharides  were fractionated  by charge 
into  species  containing  one, two, or three [3H-acetyl]Neu5, 
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Figure I. Natural and synthetic modifications of sialic acid and their 
interactions with recombinant derivatives of CD22/~ and influenza 
CHE. The most common form of  sialic acid, Neu5Ac (structure A), 
may be naturally modified by an O-acetyl-transferase to produce 
Neu5,9Ac2 (structure D). Under conditions of mild periodate oxi- 
dation (3 mM, pH Z0, 4°C), the exocyclic side chain of Neu5Ac 
is selectively oxidized to produce eight and seven carbon products 
(structures B and C, respectively). The 9-O-acetyl group protects 
the  side  chain  of Neu5,9Ac2 from oxidation.  The  binding  of 
oligosaccharides with a2-6 linked Neu5Ac residues to CD22~, as 
well as its abrogation by periodate oxidation, have been previously 
demonstrated (27, 28). The inability of oligosaccharides with c~2- 
6-1inked Neu5,9Ac2 to bind to CD22/~ is demonstrated in Figs. 
2-4.  The  binding of CHE-FcD  to  glycoconjugates containing 
Neu5,9Ac2 residues has been demonstrated (17). CHE-Fc hydro- 
lyzes the 9-O-acetyl groups (shown by the arrow from structure D 
to structure A), and it does not bind to any of these structures (17). 
For simplicity, only the relevant portions of structures B, C, and D 
are not shown. 
9Ac~ residues. Portions of the molecules containing only one 
[3H-acety/]Neu5,9Ac2  residue were then sialylated to com- 
pletion with nonlabeled CMP-Neu5Ac (non-O-acetylated) 
and o~2-6 STN. 
The binding of these structurally defined oligosaccharides 
to  CD22BRg  was  examined  using  the  column  assay.  As 
demonstrated previously (27,  28),  the elution of an oligo- 
saccharide  containing  a  single  ot2-6-1inked  [3H]Neu5Ac 
residue is slightly but consistently retarded relative to the 
nonbinding sugar [~4C]ManNAc, indicating a weak but sig- 
nificant binding (Fig. 2 A). However, a similarly prepared 
oligosaccharide with a  single ¢2-6-1inked Neu5,9Ac2  resi- 
due coelutes with [t'C]ManNAc (Fig.2 B), indicating that 
the O-acetyl group abrogated detectable binding. An oligo- 
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Figure 2.  CD22fl interactions with monosialylated triantennary 
oligosaccharides.  Monosialylated  triantermary  oligosaccharides 
containing  either  ,~2-6-1inked [3H]Neu5Ac (A)  or a2-6-1inked 
[3H-acetyl]Neu5,9Ac2 (B) were prepared as described in Materials 
and Methods. Each sample was mixed with [14C]ManNAc (as a 
marker  for elution of nonbinding structures) and passed over a 
CD22~Rg-PAS column at 4°C. The arrow represents the point at 
which the column was warmed and eluted further at ambient tem- 
perature. The inset structures represent the predicted sites of sialic 
acid addition by c~2-6 STN, based on the branch specificity of this 
enzyme, as described in reference 14. Sia,  Neu5Ac; 9Ac, a 9-0- 
acetyl ester. 
saccharide with  two  a2-6-1inked  Neu5Ac  residues  elutes 
much later on this column, and its elution is enhanced by 
warming the column to ambient temperature (Fig. 3 A) (27, 
28).  In marked contrast, a population of [3H-acetyl]Neu5, 
9Ac2-1abeled  oligosaccharides  with  two  negative  charges 
elutes much earlier (Fig. 3 B). In fact 70% of this material 
coelutes with the [14C]ManNAc marker, and the remaining 
30 % coelutes at a position corresponding to structures with 
a  single  ot2-6  Neu5Ac residue (Fig.  2  A).  These slightly 
retarded oligosaccharides probably represent structures con- 
taining one pH-acetyl]Neu5,9Ac2  and one Neu5Ac residue. 
Oligosaccharides with three c~2-6-1inked Neu5Ac residues 
bind  better  (elute  even  later)  than  those  with  two  such 
residues (compare Figs. 3 A and 4 A, and see references 27, 
28). In contrast, an oligosaccharide with a single c~2-613H  - 
acetyl]Neu5,9Ac2  residue  and  two  non-O-acetylated ot2- 
6Neu5Ac residues elutes much earlier (Fig. 4 B). In fact, it 
elutes slightly earlier than a non-O-acetylated bisialylated 
structure, appearing just before warming the column to am- 
bient temperature (compare Figs. 3 A and 4 B). Explanations 
for this include the possibility that the Neu5,9Ac2 group in- 
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Figure 3. CD22/~ interactions with disialylated triantennary oligo- 
saccharides. Disialylated oligosaccharide chains were prepared as 
described in Materials and Methods and passed over a CD22/~Rg- 
PAS column as in Fig. 2. Profiles are shown for (A) chains contain- 
ing two [3H]Neu5Ac  residues and (B) a mixture of chains with one 
to  two  [3H-acty/]Neu5,9Ac2 residue  and  zero  to  one  Neu5Ac 
residues (see text for discussion). The inset structures represent the 
predicted sites of sialic acid addition for the major isomers by a2-6 
STN. Sia, Neu5Ac; 9Ac, a 9-O-acetyl ester. 
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Figure 4.  CD22/~ interactions between trisialylated triantennary 
oligosaccharides. Trisialylated triantermary oligosaccharides were 
prepared as described in Materials and Methods, and passed over 
a CD22#Rg-Pas column as in Fig. 2. Profiles are shown for chains 
containing (A) three u2-6 linked [3H]Neu5Ac residues or (B) one 
[~H-acetyl]Neu5,9Ac2 residue and two non-O-acetylated  Neu5Ac 
residues. The inset structures represent the predicted sites of sialic 
acid addition by u2-6 STN. Sia, Neu5Ac; 9Ac, a 9-O-acetyl ester. 
terferes with the binding of the other two Neu5Ac residues, 
or that an oligosaccharide containing Neu5Ac residues on 
the outer antennae (as drawn in inset, Fig. 4 B), does not 
bind as tightly as those with two Neu5Ac residues on the two 
adjacent  antennae  (as  drawn  in the  insets,  in  Fig.  3  A). 
Regardless,  these  observations  clearly  indicate  that  9-0- 
acetylation of oL  2-6-1inked sialic acids abolished their recog- 
nition by CD22/3Rg, and that the binding of multisialylated 
structures  with  a  mixture of 9-O-acetylated and  non-O- 
acetylated sialic acids is markedly reduced in comparison to 
similarly sialylated oligosaccharides with no 9-O-acetylated 
residues. 
Another  naturally  occurring sialic  acid  modification is 
hydroxylation of the N-acetyl group that generates Neu5Gc- 
(31,  44).  Since N-glycolyl-neuraminic acid is prevalent in 
mice, we asked if Neu5Gc in place of Neu5Ac alters interac- 
tions  between  CD22/~  and  its  ligands.  Using  CMP-[3H] - 
Neu5Gc and 0~2-6 STN, biantennary oligosaccharides con- 
taining  two  oL2-6-1inked  pH]Neu5Gc  were  constructed. 
Their binding to the CD22/~Rg-PAS  column was indistin- 
guishable from structures containing two Neu5Ac residues 
(data not shown). Thus, in contrast to 9-O-acetylation, this 
sialic acid modification has no inhibitory effect on CD22/~ 
recognition. 
9-O-Acetylation Masks Potential Ligands for CD22f3 
on Murine Splenocytes 
Since expression of CD22 has been previously demonstrated 
in lymph nodes and splenic B cells (7, 41), these organs may 
also contain cells with ligands for this receptor. To search 
for such ligands  and to examine the possibility that they 
might be masked by 9-O-acetyl groups,  splenocytes were 
probed by flow cytometry for CD22/3Rg staining before and 
after treatment with the CHE-Fc esterase. If 9-O-acetylation 
of ot2-6-1inked  sialic  acids  is  masking  potential  CD22~ 
ligands,  CHE-Fc treatment should remove the esters (see 
Fig.  1),  giving an increased fluorescence relative to non- 
treated cells. It is also known that 9-O-acetylation renders 
the sialic acid side chain resistant to mild periodate oxidation 
(see Fig.  1) (11). Thus, initial treatment of cells with mild 
periodate should eliminate CD22~Rg staining, while poten- 
tial ligands "masked" by 9-O-acetylation will remain intact. 
Subsequent treatment of cell surfaces with CHE-Fc should 
remove 9-O-acetyl esters, thereby unmasking these ligands 
(see Fig.  1). This sequential treatment protocol should ac- 
centuate the detection of "masked" ligands. 
Two-color flow cytometry was  performed with  spleno- 
cytes stained with CD22/3Rg and either anti-Thyl.2 (for T 
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Figure 5.  Double-staining  flow  cytometry  analysis  of murine 
splenocytes for CD22~ ligands and Thyl.2.  Murine  splenocytes 
were isolated and either (,4) sham treated; (B) treated with CHE- 
Fc; (C) treated with mild periodate, or (D) treated with mild perio- 
date followed by CHE-Fc. After treatments, the splenoeytes were 
stained with CD22~Rg (FITC-conjugated secondary antibody) and 
phyeo~rythrin-conjugated anti-Thyl.2 for flow cytometry analysis 
as described in Materials and Methods. The number in the upper 
fight hand comer of specitied quadrants represents the percentage 
of cells from the entire population analyzed. 
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Figure  6.  Double-staining  flow  cytometry  analysis  of murine 
splenocytes for CD22B ligands and B220. Murine splenocytes were 
isolated and either (A) sham treated, (B) treated with CHE-Fc, (C) 
treated with mild periodate, or (D) treated with mild periodate fol- 
lowed by CHE-Fc. After treatments, the splenocytes were stained 
with CD22BRg (FITC-conjugated secondary antibody) and pbyco- 
erythrin-conjugated anti-B220 for flow cytometry analysis as de- 
scribed in Materials and Methods. The number in the upper fight 
hand corner  of specified quadrants  represents the percentage  of 
cells from the entire population analyzed. 
cells) or anti-B220 (for B cells). Almost the entire popula- 
tion of splenic T cells stained positive for CD22BRg ligands 
(Fig. 5 A). Upon CHE-Fc treatment,  this staining does not 
obviously increase (Fig. 5 B). As expected, mild periodate 
treatment markedly reduced CD22BRg staining in all popu- 
lations  (although  •30%  of Thyl.2-positive cells remained 
marginally CD22BRg positive; Fig. 5 C). Removal of 9-0- 
acetyl groups from the periodate-treated ceils with CHE-Fc 
increased CD22BRg staining in Thyl.2-positive populations 
from 9-12% (Fig. 5 D), showing a small subpopulation with 
ligands  masked by 9-O-acetylation.  Thus,  while the great 
majority of splenic T cells express high affinity ligands for 
CD22B, only a small subset of these express ligands masked 
by 9-O-acetylatlon.  Mild  periodate  inactivation  of native 
ligands before removal of 9-O-acetyl esters is required  to 
clearly observe this population. 
In  contrast  to  the  T  cells,  staining  of Thyl.2-negative 
splenocytes (expected to be mainly B  cells) markedly  in- 
creased after removal of 9-O-acetyl esters (Fig. 5, B and D). 
In keeping with this, the majority of the B220-positive cells 
(B cells) stain significantly for CD22#Rg ligands,  and this 
population clearly increases upon treatment with CHE-Fc 
(Fig. 6, A and B). As illustrated by Fig. 6, Cand D, previous 
treatment with mild periodate accentuates the demonstration 
of this effect of the esterase. This indicates that most but not 
all splenic B cells express potential ligands for CD22B. How- 
ever,  a  significant portion  of these ligands  are masked by 
9-O-acetylation. 
Removal of 9-O-Acetyl  Esters  from Splenic 
Lymphocytes Increases CD22B-dependent  Adhesion 
As CD22BRg is believed to function as a cell adhesion mole- 
cule (39, 49),  the effect of CHE-Fc esterase treatment on 
splenocyte binding to CD22/~Rg was examined in an adhe- 
sion assay.  Isolated murine splenocytes, treated with CHE- 
Fc or buffer alone, were added to microtiter wells precoated 
with CD22~Rg (immobilized with protein A to ensure cor- 
rect orientation).  Approximately one quarter of the added 
cells bound in the absence of esterase treatment (data not 
shown).  CHE-Fc  treatment  resulted  in a  doubling  of the 
number of adherent cells (Fig. 7). The binding of both CHE- 
Fc-treated and nontreated cells was specific for CD22BRg, 
as binding was reduced by >90% by either treating the cells 
with  mild  periodate,  or by adding  cells  to  wells lacking 
CD22BRg. Thus, the masking of ligands by 9-O-acetylation 
appears to be functionally significant in altering cell adhe- 
sion to CD22/L 
In Situ Detection of  Masked and Unmasked Ligands in 
Lymphoid Tissues 
For initial clues to the functionality of this masking in im- 
mune processes, tissue sections from murine lymph node, 
spleen, and thymus were surveyed for CD22B ligands. The 
cellular phenotypes generating the morphological character- 
istics of lymphoid tissues are very well defined, particularly 
in the mouse (24, 46). We therefore identified cells express- 
The Journal of Cell Biology, Volume 126, 1994  554 Figure 7. Effect  of CHE-Fc esterase on CD22/3Rg-dependent ad- 
herence of splenocytes. Murine splenocytes were treated either 
with CHE-Fc esterase or with PBS alone, and then added (4  x 
105 cells/well) to microtiter wells that had been precoated with 
CD22/3Rg. After 30 rain at 40C, the nonadherent cells were rinsed 
off  with PBS, and the remaining adherent cells were quantitated as 
described in Materials and Methods. The binding of cells to wells 
lacking CD22/3Rg or the binding of mild periodate-treated cells to 
wells containing CD22/3Rg ranged from 2-9% of the level of bind- 
ing between control cells and CD22/3Rg. The upper level of this 
nonspecific  binding is indicated  by the horizontal dashed line. Error 
bars indicate standard deviation (n =  4). 
ing CD22# ligands on the basis of their anatomic locations, 
morphology, and hematoxylin-staining  characteristics (lym- 
phocyte nuclei stain darkly with hematoxylin counterstain, 
while dendritic/accessory cells stain relatively poorly and 
their morphology is distinctive). In parallel, we also exam- 
ined the distribution of total 9-O-acetylated sialic acids (all 
9-O-acetylated sialic acids, regardless of linkage) using the 
CHE-FcD  probe  (see  Fig.  1 for rationale).  As  described 
elsewhere,  CHE-FcD  recognizes all 9-O-acetylated sialic 
acids, regardless of linkage or the type of glyconjugate to 
which they are attached (17). In this case, the enzymatically 
active CHE-Fc serves as a negative control because it cannot 
bind stably to 9-O-acetylated sialic acids at ambient temper- 
atures (17). 
CD2213 Ligands Are Regionally Expressed on 
Marginal Zone Lymphocytes of  Spleen and Are 
Enhanced by Removal of 9-O-Acetyl  Esters 
Total 9-O-acetylated sialic acids detected by CHE-FcD were 
found to be  widely distributed in the  spleen  (Fig.  8 A). 
Within the marginal zone, a region enriched in B cells, only 
scattered lymphocytes reacted with this probe.  However, 
lymphocytes in the periarteriolar  lymphoid sheath,  a  re- 
gion enriched in T  lymphocytes, react strongly, indicating 
high levels of 9-O-acetylated sialic acids. Accessory cells 
surrounding vascular sinusoids  in the red pulp  and  scat- 
tered  throughout  the  periarteriolar  sheaths  also  express 
9-O-acetylated sialic acids. All this staining is specific for 
9-O-acetylated sialic acids because  sections  are  negative 
with CHE-Fc (Fig. 8 B). Although CHE-FcD does not de- 
tect substantial total 9-O-acetylation on marginal zone B 
cells, flow cytometry analysis (see above) and immunohisto- 
logical staining with CD22/3Rg  (see  below)  indicate that 
many splenic B  ceils do have CD22j5  ligands masked by 
9-O-acetylation.  Thus,  these  masking 9-O-acetyl  groups 
must represent a small percentage of  the total 9-O-acetylated 
sialie acids on splenic lymphocytes in general. In keeping 
with this, it has recently been shown that T ceils express a 
variety of O-acetylated gangliosides, including 9-O-acetyl- 
GD3 (18, 19,  33).  These would be detected by CHE-FcD, 
but not by CD22#Rg. 
In contrast to the widespread distribution of total 9-O-ace- 
tylated sialic acids in the spleen, CD22/3Rg ligands masked 
by 9-O-acetylation showed a regionally selective expression. 
Fig. 8 C shows that CD2213Rg ligands are highly expressed 
on marginal zone B lymphocytes, but only on a minority of 
lymphocytes associated  with the  periarteriolar  sheath  (T 
cells, or B cells migrating to marginal zones). This pattern 
is strikingly enhanced by previous CHE-Fc treatment (Fig. 
8 E), indicating that the cells in the same locations express 
masked ligands for CD22/~. Accessory cells found through- 
out the red pulp also express ligands,  some of which are 
masked by 9-O-acetylation (Fig. 8, E and F). Mild periodate 
pretreatment of sections abolished CD22/~Rg staining (Fig. 
8 D), indicating the specificity of the results. When (9-O-ace- 
tyl groups were removed by CHE-Fc after mild periodate 
pretreatment,  staining reappeared  in the same regions as 
those that were enhanced by CHE-Fc treatment alone (data 
not shown). The enhancement by pretreatment with CHE-Fc 
is not caused by nonspecific CHE-Fc binding because incu- 
bations with CHE-Fc alone gave no significant staining (Fig. 
8 B).  These immunohistological analyses corroborate the 
results with flow cytometry and cell adhesion, which indi- 
cate  that  many  splenic  B  cells  express  CD22/3  ligands 
masked by 9-O-acetylation. In addition, a  few T  cells, as 
well some accessory cells (which are not well represented in 
cells isolated for flow cytometry analysis), also express such 
masked CD22j3 ligands. The minor quantitative and qualita- 
tive differences between the results of flow cytometry, cell 
adhesion, and immunohistology most likely result from the 
differences in the sensitivity of  the assays, and/or to selective 
recovery of cells. 
CD22~ Ligands in the Lymph Node are Regionally 
Expressed and Selectively Masked 
Staining lymph node sections with CHE-FcD indicates that 
total 9-O-acetylated sialic acids are distributed mainly in 
paracortical regions, where T lymphocytes and interdigitat- 
ing dendritic or accessory cells are typically found (24, 46) 
(Fig. 9 A). While some of this staining is caused by paracor- 
tical lymphocytes, the probe also stains irregularly shaped 
cells with indistinct nuclei in areas between lymphocytes, a 
pattern typical of interdigitating dendritic cells. Peripheral 
follicles, which are B cell-enriched regions,  do not stain 
with CHE-FcD, except for a few cells with a dendritic cell 
morphology. Thus,  in contrast to the spleen,  follicular B 
cells in the lymph node do not seem to express 9-O-ace- 
tylated sialic acids. The marked staining seen in the lymph 
node hilum region is nonspecific (caused by adsorption of a 
reagent or an endogenous peroxidase not inactivated during 
processing) because it is also seen with the CHE-Fc negative 
control (Fig. 9 B). All other regions of the lymph node are 
devoid of staining with control CHE-Fc. 
The expression of total 9-O-acetylated sialic acids in the 
Sjoberg et al. O-Acetylation of CD2215 Ligands  555 Figure 8. Immunohistological analysis of  murine spleen. Frozen sections of  murine spleen were fixed and probed with the specified reagents 
as described in Materials  and Methods. (,4) x125 CHE-FcD, (B) x125 CHE-Fc, negative control, (C) xS0 CD22/3Rg, (D) x50 mild periodate 
treatment before CD22/3Rg staining,  (E) x50 CHE-Fc treatment before CD22/3Rg, (F) x250 magnification of  E showing the marginal zone. 
The arrow in F indicates a typical arteriole surrounded by a periarteriolar (pa) lymphoid sheath.  Examples of the B cell-enriched marginal 
zone (mz) and the red pulp (rp) are indicated  in A. 
The Journal of Cell Biology, Volume 126, 1994  556 Figure 9. Immunohistological analysis of  murine lymph node. Frozen sections from murine lymph node were fixed and stained as described 
in Materials and Methods. (A) x50 CHE-FcD, (B) x50 CHE-Fc, negative control, (C) x50 CD22/SRg, (D) x50 mild periodate treatment 
before CD22/~Rg staining,  (E) x50 CHE-Fc treatment before CD22/SRg, (F) x500 magnification  of E showing enhancement of dendritic 
cell-specific CD22/3Rg staining  in the paracortical region. Typical examples of follicles  (fo), paracortical zone (pc), and medulla (m) are 
indicated  in D. 
Sjoberg et al. O-Acetylation of CD22~ Ligands  557 Figure 10. Immunohistological analysis of murine thymus. Frozen sections from murine thymus were fixed and stained as described in 
Materials and Methods. (A) x125 CHE-FcD, (B) x125 CHE-Fc, negative control, (C) xS0 CD22/3Rg,  (D) x50 mild periodate treatment 
before to CD22/$Rg staining, (E) xS0 CHE-Fc treatment before CD22/~Rg, (F) x250 magnification of E showing cortical-medullary  junc- 
tion. Typical examples of the medulla (m) and cortex (c) are shown in D. 
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ligands.  CD22/3Rg  strongly  stains  peripheral  follicles  of 
lymph nodes (enriched in B cells), while the paracortical re- 
gions are essentially negative (Fig.  9  C).  This staining  is 
specific,  since mild periodate pretreatment  abrogates it in 
all areas except the nonspecificaily stained hilum (Fig. 9 D). 
Since the follicles stain so strongly with CD22/~Rg, enhance- 
ment with CHE-Fc treatment alone would be difficult to ob- 
serve.  However,  CD22/~Rg  staining  of follicles  was  not 
restored by CHE-Fc after abrogation by mild periodate treat- 
ment, indicating that 9-O-acetylation does not significantly 
mask ligands for CD22/~ on these B cells (data not shown). 
Staining  of paracortical  lymphocytes (T cell-enriched  re- 
gion) with CD22/~Rg was minimai.  However, if the colori- 
metric reaction was allowed to proceed for a longer time, 
specific reactivity was observed, suggesting a low level of na- 
tive ligand expression (data not shown). Unlike the case in 
the follicles, treatment with the CHE-Fc esterase strikingly 
increased CD22/~Rg staining in the paracortical region (Fig. 
9 E). At higher magnifications, this enhanced staining corre- 
sponds  mainly  to cells interspersed  between lymphocytes 
(interdigitating  dendritic  cells)  rather  than  with  the  peri- 
nuclear pattern typical of lymphocyte staining (Fig. 9 F). In- 
terestingly,  essentially all the CD22/~  ligands expressed by 
these accessory cells are masked by 9-O-acetylation,  sug- 
gesting that this modification may regulate interactions with 
CD22-positive B cells. 
CD22~Rg Selectively Stains the Thymic Medulla and 
Staining Is Enhanced by Removal of 9-O-Acetyl Esters 
Expression of total 9-O-acetylated sialic acids (CHE-FcD 
staining) is restricted to the medullary region of thymic tis- 
sue  sections (Fig.  10 A),  and the  specificity control  with 
CHE-Fc is negative (Fig.  10 B). At higher magnifications, 
the medullary staining is seen to be on both thymocytes and 
epithelial cells (data not shown). CD22/~Rg ligands are ex- 
pressed at low levels almost exclusively within the medulla 
(Fig.  10  C),  qualitatively  paralleling  that  of total  9-0- 
acetylated  sialic  acids.  Pretreatment  with  mild  periodate 
abolished CD22/~Rg reactivity, indicating  specificity of the 
staining (Fig. 10 D). Medullary reactivity is significantly en- 
hanced by previous removal of 9-O-acetyl esters with CHE- 
Fc (Fig. 10 E). At higher magnification, it is evident that this 
enhancement is particularly on a subset of thymocytes at the 
cortical-medullary junction and on accessory cells scattered 
throughout the medulla (Fig.  10 F).  Also,  some cells sur- 
rounding blood vessels (possibly mast cells) stain strongly 
for CD22/$Rg only after removal of 9-O-acetyl esters. As be- 
fore,  the  enhancement  of CD22/~Rg  staining  by  CHE-Fc 
treatment is specific for its esterase activity because no stain- 
ing is observed when sections are treated with CHE-Fc alone 
(F~_g. 10 B). Thus, medullary thymocyte~, p~rticularly at the 
cortical-medullary junction,  as well as some medullary ac- 
cessory cells, express ligands for CD22~ that are masked by 
9-O-acetylation. 
Discussion 
Previous reports using CD22/~Rg as a probe to detect ligands 
were limited to T and B lymphoma cell lines and to human 
peripheral  blood T  cells (2,  34,  39).  Supporting the func- 
tionai relevance of these findings, reactivity with CD22/~Rg 
correlated with adhesion of cells to CD22/3-transfected COS 
cells.  Antibodies directed against  CD22 itself have shown 
that its expression is mainly on primary and secondary follic- 
ular B cells.  In contrast,  interfollicular  regions within the 
medulla and paracortical  regions of lymph nodes were not 
reactive (7). Staining of mantle zone B cells was more promi- 
nent than on germinal center B cells, suggesting that CD22 
surface expression is lost after B cell activation. In this study, 
we have reported the direct detection of potential ligands for 
CD22  in  lymphoid  tissues  and  their  masking  by  9-0- 
acetylation of sialic acids. 
In most previously studied interactions between lymphoid 
cells,  the receptor/ligand  pairs have extracellular  integrin- 
like or Ig-like domains that mediate adhesion through pro- 
tein-protein  interactions  (37).  CD22/~  contains  seven  Ig 
domains and can mediate adhesion to a variety of hemato- 
poietic cells  (8,  38,  39).  The  recombinant  chimeric  form 
CD22/~Rg contains  the three Ig domains required  for cell 
adhesion,  and  precipitates  several  glycoproteins  from  la- 
beled cells,  including  CD45RO,  a  protein  tyrosine phos- 
phatase  (2,  43).  However,  CD22/~  mediates  adhesion  to 
CD45RO-negative cells as well (8,  27,  34,  39).  This  and 
other data indicate that CD22/3 interacts with a variety of dis- 
tinct glycoprotein ligands.  All such interactions  studied to 
date are abolished by sialidase treatment or by mild periodate 
oxidation (2, 8, 27, 34, 39), which can selectively cleave the 
side chain of sialic acids, even on intact cell surfaces. The 
critical role of o~2-6-1inked  sialic acids in these interactions 
(27,  28)  is  further  confirmed  here  by the  effects of 9-0- 
acetylation, a natural modification. 
The o~2-6 STN transfers sialic acids from CMP-sialic to 
Gal/~I-4GlcNAc  sequences  commonly  found  at  the  non- 
reducing  termini  of N-linked  oligosaccharides  (48).  The 
number and proportion of such residues depends on many 
factors, including the level of Golgi ot2-6 STN, competing 
terminal  transferases,  the Golgi localization  of ot2-6 STN 
relative  to  competing  enzymes,  the  availability  of CMP- 
sialic acid in the Golgi lumen, the nature and amount of the 
polypeptide  acceptors  available,  and  their  rate  of transit 
through the Golgi. Regardless, oligosaccharides with multi- 
ple ot2-6 siaiic acids are relatively common on glycoproteins 
(14).  While this may explain the multiplicity of the natural 
glycoprotein ligands recognized by CD22/3, it does not ex- 
plain why the great majority of cellular glycoproteins are not 
good ligands (27, 42). Thus, additional mechanisms must ex- 
ist by which CD22/~-glycoprotein interactions are regulated. 
Several possibilities  exist that are not mutually  exclusive. 
First, CD22/~ may recognize not only ct2-6-sialylated oligo- 
saccharides, but also a certain conformation or sequence in 
the underlying  protein.  Second,  the protein  may act as a 
"scaffold" to present the oligosaccharides in a specific pattern 
that  is  best  recognized  by  CD22/L  Third,  high  affinity 
ligands for CD22/3 may simply contain several N-linked oli- 
gosaccharides  with  tx2-6-1inked  sialic  acids.  Finally,  the 
a2-6-1inked sialic acids might be modified to temporarily or 
permanently abolish interactions.  This manuscript provides 
evidence for the last possibility. 
Since  the  exocyclic  side chain  of sialic  acid  is  known 
to be required  for recognition,  it is satisfying to find that 
side-chain 9-O-acetylation can abrogate recognition of ot2- 
6-1inked sialic acids by CD22/L Interestingly, solution con- 
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NMR indicate that the sialic acid moiety folds back on the 
underlying oligosaccharide backbone because of flexibility 
of the glycosidic linkage between galactose and siaiic acid. 
This causes the side chain of sialic acid to protrude into 
space away from the oligosaccharide backbone(4, 30), per- 
haps allowing access for recognition by CD22/3.  Although 
the solution conformation of 9-O-acetylated sialyl ot2-6N- 
acetyl-lactosamine  has not been solved, it is easy to conceive 
that addition of a hydrophobic, bulky acetyl ester to the C9 
hydroxyl group would disrupt the CD22/3 interaction. 
We also show here that 9-O-acetylation is in a position to 
modulate CD22/3 interactions in lymphoid tissues in vivo. In 
the spleen, B cells are the predominant class of cells express- 
ing masked (9-O-acetylated) ligands for CD22/SRg. In con- 
trast to splenic B cells, lymph node-associated follicular B 
cells expressed CD22/3 ligands, none of which were masked 
by 9-O-acetylation.  Thus,  masking of CD22/3  ligands by 
9-O-acetylation is differentially regulated on the same cell 
type between two different lymphoid organs. 
When CHE-FcD was used to detect total 9-O-acetylated 
siaiic acids, the reactivity was more widespread, and did not 
follow the same pattern as that of CD22/3 ligands. Thus, most 
of the 9-O-acetyl esters on splenic and lymph node-derived 
cells are on molecules other than CD22/3 ligands. In keeping 
with this, although most T cells expressed only low levels of 
O-acetylated CD22/3 ligands, many had high levels of total 
9-O-acetylated sialic acids. These are presumably on other 
O-acetylated molecules, such as CDw60, which has recently 
been shown to be related to the ganglioside 9-O-acetylated 
GD3 (18, 19). This alSO supports our previous work indicat- 
ing that different cell types express O-acetylation of sialic 
acids only on specific classes of glycoconjngates (5, 21), and 
that even within these classes, it is expressed only on specific 
sialic acid residues (35).  Thus, 9-O-acetylation of CD22/3 
ligands is unlikely to by a nonspecific consequence of gen- 
eral O-acetylation of sialic acids in the cell type in question. 
Rather, it is likely to be a regulated event, presumably meant 
to fulfill some modulatory function on CD22/3-mediated bi- 
ology.  The  adhesion  assays  presented  here  indicate that 
CD22/3-dependent  intercellular  adhesion  may  be  one  of 
these functions. Further analysis will be required to deter- 
mine the effect of masking CD22/3 ligands on the process of 
B cell activation. Within the thymus, low but distinct expres- 
sion of CD22/3 ligands was seen almost exclusively in medul- 
lary thymocytes and epithelial cells.  Since medullary thy- 
mocytes are  mature  relative  to  cortical  thymocytes, this 
indicates that CD22/3 ligands are induced as thymocytes ma- 
ture. Treatment with CHE-Fc greatly enhanced this staining, 
particularly on a subset of thymocytes at the cortical-medul- 
lary junction. 
The primary goal of this work was to see if 9-O-acetyl- 
ation could affect the binding of CD22/3 to either synthetic 
or natural ligands. A complete analysis of the phenotypes of 
all the different subsets of cells in the lymphoid organs in re- 
lation to CD22/3 ligand expression is needed in the future. 
However,  since different cell types are segregated into dis- 
tinct microdomains within lymphoid tissues (10, 24,  46), 
some further conclusions and speculations can be made. Al- 
though specific accessory cell markers were not used in this 
study, CD22/3Rg  staining of these cells was identifiable by 
their characteristic staining in an interdigitating pattern be- 
tween lymphocytes, particularly locations within the tissues 
(6, 10, 24, 46). In all of the lymphoid tissues, accessory cell 
staining  with  CD22/3Rg  was  significantly  enhanced  by 
removal of 9-O-acetyl esters. In the spleen and thymus, this 
masking is partial, whereas essentially all the ligands on in- 
terdigitating dendritic cells of the lymph node are masked. 
Since CD2215 may function both as an adhesion protein and 
as an activation molecule (25, 26), immune cells may nega- 
tively regulate these events by inducing the expression of 
9-O-acetyl esters on CD22/3 ligands. For example, the cross- 
linking of CD22/3 by interaction with ligands on accessory 
cells could facilitate B cell activation, as well as a response 
by the accessory cells. If so, the expression of 9-O-acetyl es- 
ters would negatively regulate these initial activation events 
(6, 20, 32).  In particular, the extensive masking of ligands 
on paracorticai dendritic cells of the lymph node could pre- 
vent inadvertent interactions between these cells and naive 
B cells expressing CD22/3,  which have to migrate through 
the paracortical region before follicular localization (24, 46, 
50). Also, if thymocytes within the cortical-medullary  junc- 
tion are those just preparing to enter the circulation, the 
masking of CD22/3 ligands by 9-O-acetylation may be bene- 
ficial to avoid interactions with naive CD22-positive B cells 
before encountering antigens presented by accessory cells. 
Finally, the molecular mechanisms by which lymphocytes 
within lymphoid tissues are segregated into distinct micro- 
domains (10, 46) are currently unknown. If interactions be- 
tween CD22/3 and its et2-6-sialylated counterreceptors on T 
or B lymphocytes help to generate follicular morphology 
(49), 9-O-acetylation could modulate the entry of lympho- 
cytes into this domain. A detailed study of 9-O-acetylation 
of CD22/3 ligands during the ontogeny of B and T cells is 
needed to address these speculations. 
Since CD22/3  mediates adhesion by recognition of a2- 
6-1inked  sialylated oligosaccharides,  immune  cells  may 
modulate interactions by coordinating the expression of tx2-6 
STN and by 9-O-acetylation of its product. The distribution 
of CD75, CD76, and HB6 (antibody epitopes recognized in 
a ot2-6--linked sialic acid dependent manner) indicates that 
ot2-6 STN is expressed to some extent in B cells of varied 
maturation states (3). However,  studies of ot2-6 STN RNA 
and of the enzyme protein (1, 9, 47) indicate that ot2-6 STN 
expression in lymphocytes is extensively regulated. While 
the regulation of T  lymphocyte-associated ot2-6 STN ex- 
pression has not been analyzed carefully, activation with 
phytohemagglutinin causes induction of CD2215 ligands on 
these cells (39). Of course, this could represent expression 
of the correct glycoprotein acceptors rather than upregula- 
tion of the ¢x2-6 STN. Alternatively, other transferases, such 
as Gal/31-4GlcNAc:c~2-3 STN (48), which compete for the 
same substrate as 0t2-6 STN (but confer no interaction with 
CD22/3),  may decrease,  thereby upregulating ligands  for 
CD22J3.  The current work demonstrates that addition of 
9-O-acetyl esters is another potential mechanism to alter cell 
phenotypes from high  affinity  to low affinity states for recog- 
nition by CD22/3-positive  B cells. Very little is known about 
the regulation of 9-O-acetylation of sialic acids on lympho- 
cytes. In other systems, O-acetyl esters on sialic acids are 
generated by transfer of acetate, donated from cytosolic ace- 
tyl CoA to the C7 and C9 hydroxyl groups of terminal sialic 
acids on glycoconjngates within the lumen of the Golgi ap- 
paratus or Golgi-like elements (36, 44). When 7-O-acetyl es- 
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taneously  migrate  to the more stable position at  the  C9 
hydroxyl (16). Thus, in the case of CD22/5-mediated  interac- 
tions, 7-O-acetyl  esters are unlikely to be of practical conse- 
quence. 
Although our study has used the human form of CD22~, 
the murine equivalent is >70 % homologous (41), and it inter- 
acts with ligands in a sialic acid-dependent manner (Stamen- 
kovic, I., personal  communication). We therefore chose to 
first study the lymphoid system of a defined murine strain. 
Further  work  will  determine  if  9-O-acetylation  masks 
CD22/3 ligands in human lymphoid tissues as well. Although 
O-acetylation is generally thought to be more prevalent in ro- 
dents, 9-O-acetylated sialic acids have been reported on hu- 
man  lymphocytes  (15)  and  on  certain  malignant  human 
rumors (44). Interestingly,  lymphocytes from humans with 
certain  malignancies  express  markedly  elevated  levels  of 
9-O-acetylated  sialic  acids  (13,  40).  If these increases  of 
9-O-acetylation are occurring on lymphocyte-associated si- 
alylated ligands for CD22/3, they could negatively  modulate 
the role of CD22/3 in immune responses, generating a mech- 
anism for tumor cells to evade immune surveillance. 
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